Commit Biologics
Business Services · Denmark · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Universitetsbyen 83, Aarhus C, Region Mi...Phone Number
+45 30497099Website
www.commitbio.comRevenue
$5.1 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Commit Biologics
Founded in 2021, Commit Biologics is a biotech spin-out from Aarhus University in Denmark – an academic institution with a global reputation in complement system biology from more than three decades of complement research. The Commit team combines expertise in antibody development and complement research to develop a new type of therapeutics to treat cancer and autoimmune diseases.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Commit Biologics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Commit Biologics launches new products
Website visits: Recent activity has been detected on your website
Commit Biologics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Commit Biologics recently announced quarterly report
Funding: Get notified immidiatlly once Commit Biologics has new funding data
Check out if Commit Biologics is spiking on competitors!
Check if Commit Biologics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Commit Biologics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Commit Biologics
Recommended Actions
Find VP level buyers at Commit Biologics
Find more new buyers
Company Profile Activity
Activity Insights
Commit Biologics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Commit Biologics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Commit Biologics.
Commit Biologics financials insights
Gather financial insights about Commit Biologics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Angel/Seed
$22.2M
Commit Biologics Tech Stack
A closer look at the technologies used by Commit Biologics
Most Recent Scoops
Lateral Move
Executive Move
Executive Moves, Lateral Move
New Hire
Executive Move
Executive Moves, New Hire
Lateral Move
Executive Move
Executive Moves, Lateral Move
New Hire
Executive Move
Executive Moves, New Hire
Lateral Move
Executive Move
Executive Moves, Lateral Move
Commit Biologics News & Media
Commit Biologics achieves proof-of-concept for novel Complement Engager platform in non-human primates
Novel approach harnessing the power of the complement system to drive potent cell depletion Single-dose study shows rapid and sustained immune cell depletion in blood and tissues with a very favourable safety profile Commit Biologics' CEO Mikkel Wandahl Pedersen to present data at PEGS...Commit Biologics appoints leading industry experts to newly formed Scientific Advisory Board
Industry and scientific experts in molecular biology, immunology and antibody research appointed to help develop Commit's BiCE™ technology platform to treat autoimmune disease and cancer Leading antibody expert Janine Schuurman to co-chair Commit's Scientific Advisory Board alongside...Commit Biologics announces €5.5m seed financing extension investment by Korys to further develop its Bispecific Complement Engaging (BiCE™) platform
Additional funding from new investor Korys, joining existing syndicate members Novo Holdings and Bioqube Ventures, brings total seed financing to €21.5m Funds will be used to further develop Commit's BiCE platform and move towards drug candidate (DC) selection Eva Van Overmeire, Senior...Commit Biologics appoints accomplished R&D executive, Dr Janine Schuurman, to its Board of Directors
Former senior vice president of antibody research at Genmab who has co-invented numerous FDA-approved therapeutic antibodies and as well as its DuoBody® bi-specific antibody platform Brings decades of experience in developing strong pipelines of antibody-based drugs from platforms,...
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Commit Biologics
Sign Up For FreeTo access detailed company insights
Founded in 2021, Commit Biologics is a biotech spin-out from Aarhus University in Denmark – an academic institution with a global reputation in complement system biology from more than three decades of complement research. The Commit team combines expertise in antibody development and complement research to develop a new type of therapeutics to tre... Read More
